Screening and treatment for Staphylococcus aureus in patients undergoing hemodialysis: a systematic review and meta-analysis
- PMID: 25519998
- PMCID: PMC4289586
- DOI: 10.1186/1471-2369-15-202
Screening and treatment for Staphylococcus aureus in patients undergoing hemodialysis: a systematic review and meta-analysis
Abstract
Background: This study was performed to evaluate the effectiveness of surveillance for screening and treatment of patients with chronic kidney disease undergoing hemodialysis and colonized by Staphylococcus aureus.
Methods: A systematic review and meta-analysis were performed. The literature search involved the following databases: the Cochrane Controlled Trials Register, Embase, LILACS, CINAHL, SciELO, and PubMed/Medline. The descriptors were "Staphylococcus aureus", "MRSA", "MSSA", "treatment", "decolonization", "nasal carrier", "colonization", "chronic kidney disease", "dialysis", and "haemodialysis" or "hemodialysis". Five randomized controlled trials that exhibited agreement among reviewers as shown by a kappa value of >0.80 were included in the study; methodological quality was evaluated using the STROBE statement. Patients who received various treatments (various treatments group) or topical mupirocin (mupirocin group) were compared with those who received either no treatment or placebo (control group). The outcomes were skin infection at the central venous catheter insertion site and bacteremia.
Results: In total, 2374 patients were included in the analysis, 626 (26.4%) of whom were nasal carriers of S. aureus. The probability of S. aureus infection at the catheter site for hemodialysis was 87% lower in the mupirocin group than in the control group (odds ratio [OR], 0.13; 95% confidence interval [CI], 0.05-0.34; p<0.001). The risk of bacteremia was 82% lower in the mupirocin group than in the control group (OR, 0.18; 95% CI, 0.08-0.42; p<0.001). No statistically significant difference in bacteremia was observed between the various treatments group (excluding mupirocin) and the control group (OR, 0.77; 95% CI, 0.51-1.15; p=0.20).
Conclusions: Twenty-six percent of patients undergoing hemodialysis were nasal carriers of S. aureus. Of all treatments evaluated, topical mupirocin was the most effective therapy for the reduction of S. aureus catheter site infection and bacteremia in patients undergoing chronic hemodialysis.
Figures





Similar articles
-
Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis.BMC Nephrol. 2016 Aug 15;17(1):115. doi: 10.1186/s12882-016-0329-0. BMC Nephrol. 2016. PMID: 27527505 Free PMC article.
-
Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers.Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD006216. doi: 10.1002/14651858.CD006216.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843708 Free PMC article.
-
Interventions for preventing infectious complications in haemodialysis patients with central venous catheters.Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006894. doi: 10.1002/14651858.CD006894.pub2. Cochrane Database Syst Rev. 2010. PMID: 20091610
-
Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carriers.Cochrane Database Syst Rev. 2017 May 18;5(5):CD012462. doi: 10.1002/14651858.CD012462.pub2. Cochrane Database Syst Rev. 2017. PMID: 28516472 Free PMC article.
-
Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients.Cochrane Database Syst Rev. 2017 Apr 8;4(4):CD004679. doi: 10.1002/14651858.CD004679.pub3. Cochrane Database Syst Rev. 2017. PMID: 28390069 Free PMC article.
Cited by
-
Prevalence of Nasal Staphylococcus aureus Carriage in Patients Undergoing Hemodialysis and Assessment of Risk Factors: A Cross-Sectional Study of Outpatients at a University Hospital.Healthcare (Basel). 2025 Jan 26;13(3):245. doi: 10.3390/healthcare13030245. Healthcare (Basel). 2025. PMID: 39942434 Free PMC article.
-
Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review.J Antimicrob Chemother. 2019 Feb 1;74(2):281-294. doi: 10.1093/jac/dky421. J Antimicrob Chemother. 2019. PMID: 30376041 Free PMC article. Review.
-
Analysis of the dynamics of transition from non-colonization to colonization and Staphylococcus aureus bacteremia in hemodialysis patients using Markov models.F1000Res. 2025 Jan 6;13:837. doi: 10.12688/f1000research.151896.3. eCollection 2024. F1000Res. 2025. PMID: 39931330 Free PMC article.
-
Selection of Staphylococcus aureus in a murine nasopharyngeal colonization model.Front Cell Infect Microbiol. 2022 Aug 4;12:874138. doi: 10.3389/fcimb.2022.874138. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35992161 Free PMC article.
-
Antimicrobial resistance in nephrology.Nat Rev Nephrol. 2019 Aug;15(8):463-481. doi: 10.1038/s41581-019-0150-7. Nat Rev Nephrol. 2019. PMID: 31086308 Free PMC article. Review.
References
-
- Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Stud Group. 2001;344(1):11–6. - PubMed
-
- Roberts S, West T, Morris A. Duration of methicillin-resistant Staphylococcus aureus colonization in hospitalised in patients. New Zeland Med J. 2004;117:1195. - PubMed
Pre-publication history
-
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/15/202/prepub
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical